Please assess the completion status of the following clinical trial:

Trial Title: Use of Exenatide and Pramlintide to Decrease Post-prandial Hyperglycemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Age of 12 to 21 years.~2. HbA1C less than 9%~3. Subjects must be on intensive insulin management~4. Tanner stage greater than or equal to 3~5. Having Type 1 Diabetes for at least one year~6. Type 1Diabetes defined by ADA criteria and having at least one of the following antibodies a. Anti-GAD (glutamic acid decarboxylase) b. Anti-islet cell 512 (ICA512) c. Anti-insulin~7. Willing to give consent.~Exclusion Criteria:~1. Type 2 diabetes.~2. Having any other chronic condition except hypothyroidism stable on medications.~3. On chronic medications that may affect glucose excursions.~4. Anemia as defined as Hb less than 9 gm/dl.~5. Abnormal amylase, lipase or creatinine (twice normal).~6. Abnormal Liver function tests(three times above normal)~7. Unsupportive family environment as determined by clinicians and/or social workers.~8. Pregnant or lactating mothers

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Pramlintide + Insulin Group (Type: EXPERIMENTAL): These kids will get Pramlintide (Symlin) along with insulin before breakfast and supper.
- Exenatide + Insulin Group (Type: EXPERIMENTAL): This group will get Exenatide(Byetta) along with insulin before breakfast and supper.
- Insulin monotherapy (Type: ACTIVE_COMPARATOR): This group will be on their regular insulin therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).